BerGenBio extends Phase II trial with bemcentinib and KEYTRUDA® in NSCLC to include patients with disease progression on immune checkpoint inhibitor therapy
· First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy · New cohort added under existing collaborative agreement with Merck assessing the combination in previously treated advanced NSCLC · Decision to extend driven by encouraging preclinical data and high unmet need for treatment options after anti-PD(L)1 failureBergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in an